The COVID Cicada variant is making the rounds. Health officials are tracking the COVID Cicada variant closely as cases spread — this one’s being called Cicada, named for its apparent ability to emerge in force after a long period of quiet spread. It’s been detected in approximately half of US states, and case counts are climbing globally. Health authorities are tracking it closely, though the tone is watchful, not alarmed.
What We Know About the Cicada Variant
Cicada is a descendant of the Omicron family, carrying mutations that set it apart from the strains that dominated last winter. Lab studies suggest it has a growth advantage — it spreads faster than its immediate predecessors. Within weeks of being flagged, it had appeared in multiple regions simultaneously — a pattern that typically indicates widespread travel spread or convergent evolution.
Current data suggests Cicada is more transmissible but not more severe than the variants it is replacing. Most infections appear mild, particularly in people with prior vaccination or previous COVID infection.
Symptoms and How They Compare
Cicada’s symptom profile looks similar to what millions of people have already experienced: fever, cough, fatigue, body aches, and nasal congestion. Some patients report sore throat. Headache and loss of taste or smell — once hallmark signs of COVID — appear less frequently with Cicada than with earlier variants.
The incubation period is roughly two to four days from exposure to symptom onset. Most people who get sick recover at home within a week or two. Cases that progress tend to involve the same high-risk groups as before: older adults, immunocompromised individuals, and people with underlying respiratory or cardiovascular conditions.
How Effective Are Vaccines Against Cicada?
The updated vaccines targeting XBB variants — the shots made available in fall 2023 — appear to retain meaningful effectiveness against Cicada. They aren’t perfect, and nobody should expect sterilizing immunity. But they substantially reduce the risk of severe disease and death, which remains the primary goal of COVID vaccination in the current phase of the pandemic.
Previous infection provides some cross-protection, though natural immunity from earlier variants is less reliable against Cicada than against near-relatives like Delta or BA.5. If your last infection or vaccination was more than a year ago, a booster dose is worth discussing with your doctor.
What You Should Actually Do Right Now
No need to stock up on toilet paper or revert to 2020 mindset. But a few practical steps are worth considering. If you’re eligible for a COVID booster and haven’t gotten one recently, now is a reasonable time — especially ahead of spring travel or large indoor gatherings. Rapid antigen tests are widely available and worth keeping around. If you develop symptoms, testing early gives you the option to start Paxlovid within the five-day treatment window.
The Bigger Picture
Cicada isn’t a new crisis — it’s the latest evolution of a virus that has permanently joined the ecosystem of respiratory pathogens humans manage every year. Seasonal COVID vaccination, like flu shots, is likely to become a regular recommendation for the foreseeable future — particularly for older and higher-risk populations.
What we know for certain is that the world has largely moved on. Most people have stopped masking. Vaccine fatigue is real. And yet the virus keeps finding ways to spread. How we navigate that gap — between the world we want to live in and the viral reality we actually inhabit — is a question every society is still working through. Cicada is just the most recent reminder that the question isn’t going away.
GIPHY App Key not set. Please check settings